
EHMEThealth

Mission

Provide breast cancer patients access to radiation therapy that is simple to use, highly effective, and cost-efficient.

Ehmet's MammoKnife™ is designed to deliver precision radiotherapy while reducing or eliminating damage to the heart and lungs.

"Women with breast cancer may be at increased risk of cardiovascular disease, including heart failure," *American Heart Association.*

EHMEThealth

Psychological Impact…..Trauma

“How am I going to look after treatment?”

“How will I get there everyday?”

“How does this negatively affect my health?”

“What will I look like after?”

“What will this do to my body?”

“How will treatment impact my life?”

EHMEThealth

Current Standard of Care

- May damage the heart and lungs through the chest wall because patient is frequently dosed in supine or “face up” position.
- Even when treatment is performed in a prone or “face down” position, current radiation therapy devices have limited access to the breast.
- May damage healthy skin and breast tissue given limited access, requiring one or more reconstructive surgeries with undesirable outcomes and secondary complications.



Supine



Prone

EHMEThealth

Current Standard of Care

Current Radiotherapy for Breast Cancer

Not designed for specific anatomy of every breast. *Current devices have limited access to the breast (two field) and are not optimum for delivering modern treatment methods (Hypofractionation/Ultra-hypofractionation) —advanced techniques already used in other types of cancer such as prostate and brain with Linacs, CyberKnife, and Gamma Knife procedures.*

Costly to install, operate, and maintain. *Site preparation and buildout for current radiotherapy devices can exceed $3 million. It entails a lengthy permitting process and requires shielded bunkers, numerous dedicated support staff, and substantial infrastructure.*

EHMEThealth

Proven Need for a Prone Solution

Ehmet's founders developed the first contoured treatment board designed for prone radiation treatment to the breast. The resulting data and interaction with leading global oncology centers was the genesis for the "MammoKnife." It represents the next level of evolution in breast radiotherapy and what will be the gold standard in the treatment of breast cancer, designed to improve patient experiences and ultimately result in improved outcomes.

The board defined prone treatment

- Over 150 installations
- Dozens of clinical papers
- Over 100,000 patients treated
- Patented, 510(k), and CE marked

EHMEThealth

MammoKnife Innovation

Ehmet Health is the *first* to offer self-shielded linear accelerators designed to treat breast cancer in the prone position with advanced techniques and *without* the need for a vault.

MammoKnife Animation

Grant Funding

The MammoKnife team developed the proof-of-concept system with a $2.1mm NIST ATP grant and is currently collaborating on follow on submittals with members of leading US cancer programs.

- NIH Small Business Innovation and Research (SBIR)
  - Phase I – proof of concept: $225K 1 year
  - Phase II – development: $1.5mm total 2-3 years
  - Above budget limits can be exceeded for cancer treatment devices

- NIH Academic / Industrial partnership grants
  - Focus on commercialization of promising technology (in contrast to research)
  - 3–5 year multimillion dollar project funding (more with NIH approval)
  - Requires at least one industry and one academic partner
  - Several grant applications anticipated
    - MammoKnife development / commercialization
    - Advanced imaging for integrated treatment planning
    - Integrated diagnostic breast imaging and biopsy

- Anticipate a mix of the above grant instruments for funding development

EHMEThealth

The MammoKnife Difference

Prone Positioning	Isolation of breast from organs at risk (heart, lung) for superior treatment and minimized secondary dose
Integrated Imaging	With integrated target imaging we reduce the need for a separate CT Simulator and allow for adaptive planning reimbursement and targeted treatment- less radiation exposure during planning process
360º Rotation	Allows for delivery of optimized non-invasive accelerated partial breast, true intensity-modulated treatment plans, multi-target techniques, and radiosurgery of the breast while sparing healthy organs, with the potential to use less dose
Self-Shielded Structure	Can be on a mobile platform allowing for a dramatically reduced cost of ownership in addition to a significantly lower installation timeframe allowing surgery centers, outpatient clinics, and breast centers to offer advanced techniques
Leverage Current Standards	Compatible with most treatment planning systems, allowing physicians to use accelerated, partial, or whole breast radiation; uses existing CPT codes for reimbursement

EHMEThealth

Integrated Shielding → Treatment Mobility

May be deployed to where the patients are; not restricted to hospital-based radiotherapy facilities

Cost pressures are forcing patients through insurance away from traditional hospitals to outpatient treatment in lower-cost, specialty-focused centers

Attractive reimbursement for therapeutic procedures in contrast to diagnostic procedures

May significantly multiply the revenue stream of free-standing specialty centers while reducing overall the cost of treatment

Potential to produce superior outcomes using less radiation dose

EHMEThealth

Mobile Breast Clinic

Mobile Platform

Click to play 3D design animation

The MammoKnife's design as a compact self-shielded device allows for deployment on a standard trailer introducing a first-of-its-kind platform for delivering precision therapy in a mobile setting.

The system, when complete, will deliver *turn-key* therapy solutions that can be deployed to any urban or rural location, partnering with community medicine and outpatient centers.

EHMEThealth

Unmet Needs: Rural Radiotherapy

One-fifth of women live in rural areas, representing 70,000 new cases

Only 3% of all radiation oncologists practice in rural areas; over 70% (2,100+) of counties in the United States do not have easy access to a radiation oncologist

Average rural patient travels an hour each way for treatment, increasing economic burden on patient, overall quality of life, and well being

The MammoKnife's compact design extends treatment options, allowing access to advanced therapy both in low-income and rural areas improving levels of care, reducing patient's costs, and producing quality outcomes

Challenges of Rural Cancer Care in the United States, Journal of Oncology, September 2015

EHMEThealth

P Cubed Value

Patient

- Better access
- Advanced treatment protocols
- Potential for better cosmetic/clinical outcome

Provider

- Low-cost patient acquisition through a new marketable device
- Economically profitable under the alternative and bundled payment models
- Immune compromised patients can be treated outside hospital setting

Payor

- Allows for lower overall cost of care with accelerated treatment options
- Rural and low-income area access to precision treatment
- Mobile unit provides community hospitals the ability to collectively share in cost

EHMEThealth

Worldwide Market

$6 Billion Market Potential

The MammoKnife market includes not only traditional treatment centers, but also surgery centers, women's health centers, and outpatient clinics already expanding service to include oncology

16,675 Estimated Global Market (Units needed for treatment of all estimated cancer cases)

- US & Canada – 3,650 Units
- European Union – 3,500 Units

Additional potential markets worldwide based on small footprint and limited facility requirements

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer Journal for Clinicians

EHMEThealth

Lumpectomy + Radiation

"For women with early-stage breast cancer…, studies indicate that breast-conserving surgery plus radiation therapy results in long-term outcomes equivalent to, and possibly even better than, mastectomy."

Cancer Facts and Figures 2018, American Cancer Society



NCI SEER Program Breast Cancer Statistics

More than 60% of patients may be candidates for lumpectomy plus precision MammoKnife radiotherapy.

EHMEThealth

Ehmet Revenue Lines

$6 Billion market, 10 Year Mammoknife Device Sales Revenue

- Estimate capturing 10% of global market in a 10-year sales period
- Pay per click model
- 1668 units sold with a $2.5M List Price = $4.2 Billion

$375 Million Annual Maintenance Revenue (8-10% of selling price)

- Maintenance revenue begins second of year of device ownership
- Device service life estimated at 7-10 years

Additional Revenue Sources

- Mobile market introduces additional direct sales or leasing options
- Leases/Click Model can be daily, weekly, or monthly depending on health centers' needs
- Provides critical alternative during global crisis

EHMEThealth

Leaders in Innovation

Products developed by team members include:
MiniCAT ENT CBCT Scanner, XCat Portable CBCT Scanner, XoranConnect Online Viewer, NeuMoDx 288 Molecular System, NeuMoDx 96 Molecular System, ClearVue Imaging Board, Mevion S250 Proton Therapy System, i-CAT Dental CBCT Scanner, PhotoElectronCorp Photon Radiosurgery System and INTRABEAM (Acquired by Zeiss International), industry first commercial 3D SPECT reconstruction and cardiac multiplanar software (Medtronic/Medical Data Systems)

EHMEThealth

Platform Technology

Ehmet Health has designed its system with inherent scalability and modularity resulting in shorter development cycles for future products and markets.

INTELLECTUAL PROPERTY

- Pediatric Extremity Treatment
- Robotic Guided Needle Biopsy
- Ultrasound Tumor Ablation

EHMEThealth

Timeline

Targeting 2-year* development period for first installation with designated NCI center, class 1, 2, and 3 FDA manufacturer and seasoned internal development team.



* - Timeline and deliverables to be refined as project progresses through design stages

EHMEThealth

Value for Partners

An expanded market reach to broader rural America and urban communities:

- Installing MammoKnife at cancer centers, outpatient surgery centers, and women's health centers allows partners to increase services and availability
- System will provide additional branding and marketing opportunities
- Corporate owned Mobile MammoKnife units could be leased to multiple health care systems creating new revenue opportunities and extending market reach for partners

Access to End-to-End data and statistics for diagnosis and treatment

- Apply AI and deep data analysis to improve effectiveness of current solutions
- Streamline future research and enable faster integration of new technologies

EHMEThealth

Achievements

2016	Ehmet Health formed with the driving premise of commercializing medical devices serving unmet needs in the medical field
2017	Awarded first multimillion-dollar contract by one of the largest healthcare systems and an NCI-designated Comprehensive Cancer Center to design and implement an advanced robotic imaging solution for a first of its kind proton radiotherapy center
2018	Received FDA 510(k) for its X-Ray positioning system and led multidisciplinary team to patient treatment at state-of-the-art proton center
2019	Further developed imaging positioning system to establish center as one of the highest volume openings over first 12 months of any proton center worldwide

EHMEThealth

Management Team

Michael Teicher, *Chief Executive Officer*, brings over 20 years of operational, financial and advisory leadership on healthcare strategy, operations, and capital markets.

Neal Clinthorne, *Chief Technology Officer*, is a world-renowned Research Professor Emeritus in Radiology from the University of Michigan. He has written nearly 100 peer reviewed articles and has been granted over 20 patents in the area of advanced medical imaging technology.

Alan Sliski, *Chief Scientific Officer*, is a prolific entrepreneur and scientist with a specialty in radiation therapy systems. Mentor in residence at the prestigious Harvard physics facility and holds 24 patents.

Michael D Kaswan, MBA, *CFO*, is a seasoned healthcare executive with nearly 20 years of finance and operational administration in both the public and private sector. Michael is a Harvard MBA and has held numerous executive roles.

Julia E. Williams, is an advisor and Global Director, Oncology Services & Solutions for ZRG Partners specializing in cancer and research for the last 18 years and is a sitting member on both National Cancer Committees advisory council to the Koman foundation.

***Collectively the founders have created devices the have generated over 7 billion dollars in revenue.**

***Clinical Advisory team available upon request**

EHMEThealth